RET (V804L)-KIF5B
Sign in to save this workspaceKIF5B-RET · Variant type: fusion · HGVS: p.Fusion;p.V804L · Fusion partner: KIF5B (V804L)
Components
p.Fusionp.V804L
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Pralsetinib | 99.8% | 0.2% | 93.43 |
| 2 | Selpercatinib | 99.6% | 0.4% | 96.72 |
| 3 | Alpelisib | 99.4% | 0.6% | 97.22 |
| 4 | Fedratinib | 99.3% | 0.7% | 96.21 |
| 5 | Entrectinib | 99.2% | 0.8% | 93.69 |
| 6 | Brigatinib | 98.9% | 1.1% | 82.96 |
| 7 | Tenalisib | 98.6% | 1.4% | 97.98 |
| 8 | Tivozanib | 97.5% | 2.5% | 92.42 |
| 9 | Sunitinib | 97.1% | 2.9% | 91.73 |
| 10 | Futibatinib | 96.9% | 3.1% | 98.48 |
| 11 | Gilteritinib | 95.8% | 4.2% | 88.97 |
| 12 | Alectinib | 93.8% | 6.2% | 95.49 |
| 13 | Regorafenib | 90.5% | 9.6% | 95.99 |
| 14 | Defactinib | 86.0% | 14.0% | 92.68 |
| 15 | Fostamatinib | 85.1% | 14.9% | 96.74 |
| 16 | Avapritinib | 83.6% | 16.4% | 97.73 |
| 17 | Baricitinib | 82.7% | 17.3% | 97.99 |
| 18 | Cabozantinib | 79.2% | 20.8% | 92.73 |
| 19 | Repotrectinib | 77.3% | 22.8% | 84.21 |
| 20 | Ruxolitinib | 76.4% | 23.6% | 98.25 |
| 21 | Lenvatinib | 59.1% | 40.9% | 97.74 |
| 22 | Capivasertib | 54.0% | 46.0% | 96.48 |
| 23 | Upadacitinib | 38.3% | 61.7% | 97.98 |
| 24 | Sorafenib | 36.0% | 64.0% | 96.72 |
| 25 | Quizartinib | 33.9% | 66.1% | 99.50 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Pralsetinib | 99.8% | — | — |
| Selpercatinib | 99.6% | — | — |
| Alpelisib | 99.4% | — | — |
| Fedratinib | 99.3% | — | — |
| Entrectinib | 99.2% | — | — |
| Brigatinib | 98.9% | — | — |
| Tenalisib | 98.6% | — | — |
| Tivozanib | 97.5% | — | — |
| Sunitinib | 97.1% | — | — |
| Futibatinib | 96.9% | — | — |
| Gilteritinib | 95.8% | — | — |
| Alectinib | 93.8% | — | — |
| Regorafenib | 90.5% | — | — |
| Defactinib | 86.0% | — | — |
| Fostamatinib | 85.1% | — | — |
| Avapritinib | 83.6% | — | — |
| Baricitinib | 82.7% | — | — |
| Cabozantinib | 79.2% | — | — |
| Repotrectinib | 77.3% | — | — |
| Ruxolitinib | 76.4% | — | — |
| Lenvatinib | 59.1% | — | — |
| Capivasertib | 54.0% | — | — |
| Upadacitinib | 38.3% | — | — |
| Sorafenib | 36.0% | — | — |
| Quizartinib | 33.9% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.3ms